The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants jeopardizes the protective antiviral immunity induced after infection or …

A SARS-CoV-2 variant carrying the Spike protein amino acid change D614G has become
the most prevalent form in the global pandemic. Dynamic tracking of variant frequencies …

Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being developed
as therapeutics and are a major contributor to neutralizing antibody responses elicited …

Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA are frequently observed
in COVID-19. However, it is unclear whether SARS-CoV-2 replicates in the human intestine …

Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …

… In contrast, the target size of the P, M, G and L genes was larger than … P corresponded to
the physical size of N+P, that of M corresponded to N+P+M, and that of G corresponded to N+P+…

An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape 1 , 2 – 3 , have
activity against diverse sarbecoviruses 4 , 5 , 6 – 7 , and be highly protective through viral …

Infections by the Ebola and Marburg filoviruses cause a rapidly fatal haemorrhagic fever in
humans for which no approved antivirals are available 1 . Filovirus entry is mediated by the …

The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-binding
domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient plasma. Little …

Antibodies are a principal determinant of immunity for most RNA viruses and have promise
to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 …